SWOG S1007: 5-yr LRR <1% with/without RNI, IDFS unaffected (HR 0.85-1.03) in Oncotype-low HR+/HER2- N1 after BCS.
SWOG S1007 secondary analysis: in Oncotype RS ≤25 HR+/HER2- N1 pts after BCS, 5-yr LRR was <1% regardless of RNI, with no IDFS signal from nodal RT in either menopausal group. Breast carried today's data, reinforcing locoregional safety of systemic de-escalation in favorable-biology early disease.
read the full digest →Studies · 33
- SWOG S1007 (RNI/LRR secondary analysis)5-yr LRR 0.55-0.85% with/without RNI after BCS; IDFS not associated with RNI in HR+/HER2- N1 favorable-biology breast cancer.
- PBS Proton vs IMRT Capsular Contracture Post-MastectomyPBS proton vs IMRT in post-mastectomy reconstruction: capsular contracture risk comparison; no effect size reported in source.
- LS-SCLC 54 Gy SIB vs 45 Gy (NCT03214003)54 Gy SIB vs 45 Gy in LS-SCLC: mOS 60.7 vs 39.5mo, HR 0.55 (0.37-0.72), p=0.003, no toxicity increase.
- Bladder-preserving TMT for MIBC — prognostic factors for recurrence and survival (ESTRO 2026)Multicenter Spanish TMT cohort (n=369 MIBC): CLR 63.7%; 5-FU-based CRT and image-guided RT predict response.
- Single-fraction SABR for primary NSCLC and lung oligometastases (pooled, n=1687)SF-SABR pooled analysis (n=1687): LC 90-93% at 2yr, G3+ AEs 2.9%, mOS 3.5yr (primary NSCLC) and >4yr (oligomets).
- ePLND vs PSMA PET staging for prostate cancer (AUA 2026)AUA 2026 review: PSMA PET NPV ~96% may safely guide ePLND omission in intermediate-risk prostate; ePLND therapeutic benefit unproven in RCTs.
- OPERA Trial (5-year rectal preservation)OPERA post-hoc: W14 DRE+rectoscopy reliably identifies cCR; 5-yr organ preservation 75% vs 83% (Arm A vs B, p=0.24).
- INRT-AIR & DARTBOARD (ENI omission in HNSCC)ENI omission via INRT in HNSCC: 5-yr elective nodal recurrence 0%, 5-yr OS 87%, 5-yr PFS 74% across 117 pts.
- TORPEdO (CRUK/18/010)TORPEdO: IMPT vs IMRT in OPSCC, no difference in patient-reported UW-QoL composite at 12 months; phase 3 RCT, N=205.
- NRG/RTOG 1005Concurrent boost during WBI noninferior to sequential boost for IBR (HR 1.31, 90% CI 0.84-2.04) with no toxicity or cosmesis penalty; saves treatment time.
- HCC EBRT multinational IPD cohortHCC EBRT multinational IPD (n=4,913): mOS 4.6yr BCLC-A, comparable to resection/ablation.
- EXTEND TrialEXTEND phase II: MDT+SOC improves PFS vs SOC across oligometastatic histologies, HR 0.54 (0.41-0.72), p<0.001, 53-mo follow-up.
- FASTRACK II (TROG 15.03)FASTRACK II: 100% local control at 36, 60, and 84 months with SABR for primary RCC (N=70, median f/u 62 mo).
- PEACE 2PEACE 2: pelvic RT did not improve cPFS vs prostate-only RT in VHR prostate (HR 0.81, p=0.088); no effect on MFS, OS, or PCSS.
- HEAT TrialHEAT: AHRT non-inferior to EHRT for BF at 4.25y interim (7% vs 7.4%, P non-inf = 0.007) in low-intermediate risk PCa.
- PACE-NODESPACE-NODES: pelvic nodal SBRT adds short-term GI toxicity (28% vs 21% G≥2) vs prostate-only SBRT; cancer control endpoint not yet mature.
- RADIOSARADIOSA post-hoc: median MFS 16.6mo vs NR, HR 0.39 favoring SBRT+ADT in oligorecurrent prostate cancer.
- PIVOTALboostPIVOTALboost phase 3: focal boost + pelvic node RT (20 fractions) safe at 2 years; G2+ late bowel/bladder similar across all arms.
- PRIMEPRIME interim: 5-fraction SBRT + whole-pelvis RT comparable to moderate hypofractionation at 1-2yr; primary BFFS endpoint immature, 4-5yr data awaited.
- PEACE-2PEACE-2: pelvic RT did not improve cPFS vs prostate-only RT (HR 0.81, p=0.088) in VHR prostate cancer with 3yr ADT.
- Dutch Breast Boost AnalysisDutch DBRT registry: 10yr IBTR 1.2% (boost vs no boost) for 0-2 RF pts post-BCS, supporting omission in modern systemic therapy era.
- HypoG-01HypoG-01 secondary analysis: patterns of failure comparable between 40 Gy/15 fx and 50 Gy/25 fx; LRR infrequent, most events were distant recurrence or second malignancy.
- DBCG HYPODBCG HYPO 10-yr: 40Gy/15fr reduced grade 2-3 induration vs 50Gy/25fr (19.5% vs 24.7%, HR 0.76, p=0.005) with no difference in recurrence or survival.
- APBI-IMRT FlorenceAPBI-IMRT Florence: 15-yr IBTR 7.7% vs 4.2% (HR 1.57, p=0.17), no difference in locoregional control, DM, or OS.
- RAPCHEMRAPCHEM 10-yr: response-adapted locoregional RT de-escalation post-NAC yields <3% recurrence in breast.
- IMPORT HIGHIMPORT HIGH 10yr: 48Gy SIB IBTR 3.7% vs sequential 3.5%; 53Gy higher at 5.5%; SIB confirmed as SOC.
- DBCG RT NaturalDBCG RT Natural: PBI 40Gy/15fr cut 4-yr LR to 1.5% vs 9.8% without RT in older ER+ pT1N0 breast cancer.
- EORTC IM-MS (22922/10925)EORTC IM-MS 20y: OS null (HR 1.00) despite BCM improvement (HR 0.82), offset by late non-BCM excess (HR 1.26).
- OLIGOMAOLIGOMA: mPFS 35.8 vs 20.4mo (HR 0.48, p=0.021) with MDT + systemic vs systemic alone in oligometastatic breast cancer.
- EXTENDEXTEND phase II RCT, MDT+SOC vs SOC in oligometastatic solid tumors: primary all-basket analysis published JCO May 2026.
- OLIGOCAREOLIGOCARE registry: SBRT for OMD, 88.6% LC at 3yr (n=2447); CRC highest local failure at 19.6%.
- DIREKHTDIREKHT: post-op RT in HNSCC with contralateral neck sparing and/or primary CTV dose reduction to 56 Gy.
- RCC SBRT 5-Year LC100% 5-year local control reported for primary RCC treated with SBRT in a single institutional series.